USCAP guidelines for hormonal receptor testing in breast cancer now recommend the report of cancers that have low (1–10%) ER-positivity to distinguish from those with higher ER expression levels in recognition of the limited data on responsiveness of the former group to endocrine therapy [36]. The gene discussed is NR4A1; the disease is breast cancer.